{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:50:36Z","timestamp":1781941836417,"version":"3.54.5"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thalassemia bone disease is a common and severe complication of \u03b2-thalassemia major (TM), resulting from marrow expansion, hormonal deficiencies, including hypogonadism, iron toxicity, and increased bone turnover. These factors contribute to reduced BMD and increased susceptibility to minimal trauma fracture (MTF). Optimizing transfusions and iron chelation therapy, management of hormonal deficiencies, and antiresorptive therapies are the cornerstone of management. We report the use of romosozumab in 2 patients with TM and severe osteoporosis. This is the first case series describing the efficacy of romosozumab in the treatment of osteoporosis in patients with TM. After completion of 12\u00a0mo of monthly romosozumab, DXA scan demonstrated significant improvements in BMD despite previous prolonged exposure to antiresorptive therapy in both subjects. This represents a promising treatment option in patients with TM and osteoporosis.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag086","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:08:26Z","timestamp":1777842506000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of romosozumab for osteoporosis in \u03b2-thalassemia major"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4184-156X","authenticated-orcid":false,"given":"Chrislyn","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences, Monash University , Clayton , Victoria 3168,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1160-1210","authenticated-orcid":false,"given":"Navira","family":"Samad","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences, Monash University , Clayton , Victoria 3168,","place":["Australia"]},{"name":"Department of Endocrinology, Monash Health , Melbourne , Victoria,","place":["Australia"]},{"name":"Hudson Institute of Medical Research , Clayton , Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Trinh","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences, Monash University , Clayton , Victoria 3168,","place":["Australia"]},{"name":"Department of Endocrinology, Monash Health , Melbourne , Victoria,","place":["Australia"]},{"name":"Hudson Institute of Medical Research , Clayton , Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9940-4376","authenticated-orcid":false,"given":"Frances","family":"Milat","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences, Monash University , Clayton , Victoria 3168,","place":["Australia"]},{"name":"Department of Endocrinology, Monash Health , Melbourne , Victoria,","place":["Australia"]},{"name":"Hudson Institute of Medical Research , Clayton , Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Sciences, Monash University , Clayton , Victoria 3168,","place":["Australia"]},{"name":"Department of Endocrinology, Monash Health , Melbourne , Victoria,","place":["Australia"]},{"name":"Hudson Institute of Medical Research , Clayton , Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"4","key":"2026062003062471800_ref1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/er.2015-1105","article-title":"Bone disease in thalassemia: a molecular and clinical overview","volume":"37","author":"Wong","year":"2016","journal-title":"Endocr Rev"},{"key":"2026062003062471800_ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.880752","article-title":"New insights into pathophysiology of \u03b2-thalassemia","volume":"9","author":"Sanchez-Villalobos","year":"2022","journal-title":"Front Med"},{"key":"2026062003062471800_ref3","doi-asserted-by":"crossref","first-page":"320737","DOI":"10.1155\/2012\/320737","article-title":"Physiopathology of bone modifications in beta-thalassemia","volume":"2012","author":"Perisano","year":"2012","journal-title":"Anemia"},{"issue":"1","key":"2026062003062471800_ref4","doi-asserted-by":"publisher","first-page":"16413","DOI":"10.1038\/s41598-023-43633-6","article-title":"Association of osteoporosis and sarcopenia with fracture risk in transfusion-dependent thalassemia","volume":"13","author":"Thavonlun","year":"2023","journal-title":"Sci Rep"},{"key":"2026062003062471800_ref5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bone.2017.10.016","article-title":"Risk of fracture in transfusion-naive thalassemia population: a nationwide population-based retrospective cohort study","volume":"106","author":"Chen","year":"2018","journal-title":"Bone"},{"issue":"8","key":"2026062003062471800_ref6","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1210\/jc.2002-021548","article-title":"Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia","volume":"88","author":"Mahachoklertwattana","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026062003062471800_ref7","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1359\/jbmr.2003.18.9.1682","article-title":"Abnormalities in bone mineral density and bone histology in thalassemia","volume":"18","author":"Domrongkitchaiporn","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026062003062471800_ref8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1359\/jbmr.080505","article-title":"Bone disease in thalassemia: a frequent and still unresolved problem","volume":"24","author":"Vogiatzi","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2026062003062471800_ref9","doi-asserted-by":"publisher","first-page":"1393865","DOI":"10.3389\/fendo.2024.1393865","article-title":"Prevalence and risk factors predisposing low bone mineral density in patients with thalassemia","volume":"15","author":"Ananvutisombat","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026062003062471800_ref10","doi-asserted-by":"publisher","first-page":"e71383","DOI":"10.1002\/hsr2.71383","article-title":"Vitamin D deficiency as a debatable modulator of outcomes in transfusion-dependent thalassemia; an overview of the latest findings: a narrative review","volume":"8","author":"Bazi","year":"2025","journal-title":"Health Sci Rep"},{"issue":"7","key":"2026062003062471800_ref11","doi-asserted-by":"publisher","first-page":"e26688","DOI":"10.7759\/cureus.26688","article-title":"Bone mineral density, serum calcium, and vitamin D levels in adult thalassemia major patients: experience from a single center in Eastern India","volume":"14","author":"Santra","year":"2022","journal-title":"Cureus"},{"issue":"4","key":"2026062003062471800_ref12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13312-019-1520-8","article-title":"Effect of vitamin D and calcium supplementation on bone mineral content in children with thalassemia","volume":"56","author":"Thiagarajan","year":"2019","journal-title":"Indian Pediatr"},{"issue":"2","key":"2026062003062471800_ref13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4274\/jcrpe.galenos.2018.2018.0074","article-title":"Pathogenesis of thalassemia major-associated osteoporosis: a review with insights from clinical experience","volume":"11","author":"Gaudio","year":"2019","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2026062003062471800_ref14","doi-asserted-by":"publisher","first-page":"1178761","DOI":"10.3389\/fendo.2023.1178761","article-title":"The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial","volume":"14","author":"Piriyakhuntorn","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026062003062471800_ref15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bone.2010.10.173","article-title":"Bone disease and skeletal complications in patients with beta thalassemia major","volume":"48","author":"Haidar","year":"2011","journal-title":"Bone"},{"issue":"5","key":"2026062003062471800_ref16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1359\/jbmr.040113","article-title":"Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle","volume":"19","author":"Morabito","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2026062003062471800_ref17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.metabol.2017.09.012","article-title":"Bone disease in beta thalassemia patients: past, present and future perspectives","volume":"80","author":"De Sanctis","year":"2018","journal-title":"Metabolism"},{"issue":"Suppl 1","key":"2026062003062471800_ref18","first-page":"144","article-title":"Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major","volume":"6","author":"Skordis","year":"2008","journal-title":"Pediatr Endocrinol Rev"},{"issue":"6","key":"2026062003062471800_ref19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00774-014-0584-8","article-title":"Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials","volume":"32","author":"Giusti","year":"2014","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2026062003062471800_ref20","doi-asserted-by":"publisher","first-page":"CD010429","DOI":"10.1002\/14651858.CD010429.pub3","article-title":"Treatment for osteoporosis in people with beta-thalassaemia","volume":"2023","author":"Bhardwaj","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062003062471800_ref21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.dib.2018.05.120","article-title":"Measurement bone mineral density (BMD) of patients with beta thalassemia","volume":"19","author":"Abbasi","year":"2018","journal-title":"Data Brief"},{"issue":"9","key":"2026062003062471800_ref22","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00198-023-06831-6","article-title":"Zoledronic acid-induced severe lymphopenia","volume":"34","author":"Karpuz","year":"2023","journal-title":"Osteoporos Int"},{"key":"2026062003062471800_ref23","doi-asserted-by":"publisher","first-page":"bcr2015213786","DOI":"10.1136\/bcr-2015-213786","article-title":"Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis","volume":"2016","author":"Kulkarni","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2026062003062471800_ref24","doi-asserted-by":"publisher","first-page":"100634","DOI":"10.1016\/j.curtheres.2021.100634","article-title":"Investigation of intravenous zoledronic acid therapy on circulating lymphocyte subpopulation in patients with primary osteoporosis: a pilot study","volume":"94","author":"Cui","year":"2021","journal-title":"Curr Ther Res Clin Exp"},{"issue":"5","key":"2026062003062471800_ref25","doi-asserted-by":"publisher","first-page":"e2022305","DOI":"10.23750\/abm.v93i5.13668","article-title":"Approach to the management of beta thalassemia major associated osteoporosis - a long-standing relationship revisited","volume":"93","author":"Yavropoulou","year":"2022","journal-title":"Acta Biomed"},{"issue":"1","key":"2026062003062471800_ref26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12967-023-04563-z","article-title":"Romosozumab in osteoporosis: yesterday, today and tomorrow","volume":"21","author":"Wu","year":"2023","journal-title":"J Transl Med"},{"issue":"15","key":"2026062003062471800_ref27","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026062003062471800_ref28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jbmr\/zjae194","article-title":"Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis","volume":"40","author":"McClung","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"3-4","key":"2026062003062471800_ref29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/07853890.2020.1744708","article-title":"Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia","volume":"52","author":"Sapunarova","year":"2020","journal-title":"Ann Med"},{"issue":"12","key":"2026062003062471800_ref30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1055\/s-0032-1312618","article-title":"High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density","volume":"44","author":"Voskaridou","year":"2012","journal-title":"Horm Metab Res"},{"issue":"9","key":"2026062003062471800_ref31","doi-asserted-by":"publisher","first-page":"102709","DOI":"10.1016\/j.clinre.2025.102709","article-title":"Evaluation of osteoporosis in adult patients with beta-thalassemia major and its relation to serum sclerostin level","volume":"49","author":"Bamby","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"2026062003062471800_ref32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00774-025-01596-w","article-title":"Romosozumab and cardiovascular safety in Japan","volume":"43","author":"Takeuchi","year":"2025","journal-title":"J Bone Miner Metab"},{"key":"2026062003062471800_ref33","doi-asserted-by":"publisher","first-page":"104697","DOI":"10.1016\/j.yrtph.2020.104697","article-title":"Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture","volume":"115","author":"Turk","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"2026062003062471800_ref34","doi-asserted-by":"publisher","first-page":"102911","DOI":"10.1016\/j.cpcardiol.2024.102911","article-title":"Thalassemia and iron overload cardiomyopathy: pathophysiological insights, clinical implications, and management strategies","volume":"50","author":"Ansharullah","year":"2025","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"2026062003062471800_ref35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/nyas.15078","article-title":"Cardiac complications in thalassemia throughout the lifespan: victories and challenges","volume":"1530","author":"Wood","year":"2023","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2026062003062471800_ref36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MPH.0000000000000467","article-title":"Early cardiac involvement and risk factors for the development of arrhythmia in patients with beta-thalassemia major","volume":"38","author":"Hamed","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10116","key":"2026062003062471800_ref37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"2026062003062471800_ref38","doi-asserted-by":"publisher","first-page":"E207","DOI":"10.1002\/ajh.25502","article-title":"Development of a thalassemia-related thrombosis risk scoring system","volume":"94","author":"Taher","year":"2019","journal-title":"Am J Hematol"},{"key":"2026062003062471800_ref39","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.tru.2022.100102","article-title":"The thrombotic spectrum of B-thalassemia","volume":"7","author":"Vasilopoulou","year":"2022","journal-title":"Thrombosis Update"},{"issue":"10","key":"2026062003062471800_ref40","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","article-title":"Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study","volume":"115","author":"Taher","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2026062003062471800_ref41","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3324\/haematol.2012.066845","article-title":"Non-transfusion-dependent thalassemias","volume":"98","author":"Musallam","year":"2013","journal-title":"Haematologica"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag086\/68244763\/ziag086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/7\/ziag086\/68244763\/ziag086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/7\/ziag086\/68244763\/ziag086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:06:28Z","timestamp":1781939188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag086\/8671999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag086","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,7]]},"article-number":"ziag086"}}